Meiting Chen, Lu Li, Qing Xia, Xiaobing Chen, Zijun Liao, Chang Wang, Bo Shen, Min Zhou, Qingyuan Zhang, Yanqiao Zhang, Liting Qian, Xianglin Yuan, Zhehai Wang, Cong Xue, Xin An, Bin Liu, Kangsheng Gu, Mei Hou, Xiaojia Wang, Wei Wang, Enxiao Li, Jincai Zhong, Jing Cheng, Yongqian Shu, Nong Yang, Huaqing Wang, Runxiang Yang, Tianshu Liu, Ting Deng, Fei Ma, Wangjun Liao, Wensheng Qiu, Yu Chen, Xi Chen, Mingzhi Zhang, Ruilian Xu, Xiaoling Li, Jifeng Feng, Yi Ba, Yanxia Shi
BACKGROUND: Studies on various thrombopoietic agents for cancer treatment-induced thrombocytopenia (CTIT) in China are lacking. This study aimed to provide detailed clinical profiles to understand the outcomes and safety of different CTIT treatment regimens. METHODS: In this retrospective, cross-sectional study, 1664 questionnaires were collected from 33 hospitals between March 1 and July 1, 2021. Patients aged >18 years were enrolled who were diagnosed with CTIT and treated with recombinant interleukin 11 (rhIL-11), recombinant thrombopoietin (rhTPO), or a thrombopoietin receptor agonist (TPO-RA)...
March 22, 2024: Cancer